Tandem Diabetes Care Announces Fourth Quarter and Full Year 2019 Financial Results and 2020 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tandem Diabetes (TNDM) Tops Q4 EPS by 9c, Revenues Miss; Offers FY20 Revenue Guidance Above Consensus
February 24, 2020 4:11 PM ESTTandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.04, $0.09 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $108.4 million versus the consensus estimate of $109.22 million.
In comparing the fourth quarter of 2019 to the same period of 2018:
Worldwide pump shipments increased 21 percent to 19,602 pumps from 16,168 pumpsSales increased 42 percent to $108.4 million from $76.2 millionGross margin improved 1 point to 56 percent of sales... More